CD8A and melanoma: The clinically approved oHSV talimogene laherparepvec in melanoma patients caused increased CD8+ T cell density in tumors which positively correlated with patient response to combinatorial oHSV and anti-PD-1 checkpoint immunotherapy23, indicating potential avenues to explore CD8-targeted PET imaging to assess responses to oHSV in models of melanoma and other solid tumors that undergo immunotherapy interventions.